Simpler Grants.gov #PAR-25-374

NIH Grant for Preclinical Drug Testing in Alzheimer's Disease and Related Dementias

This opportunity from the National Institutes of Health (NIH) supports research to advance drug repurposing and combination therapy development for Alzheimer's Disease and Related Dementias (AD/ADRD): - Government Buyer: - National Institutes of Health (NIH) - Products/Services Requested: - Preclinical testing of drugs or drug combinations using mouse models for AD/ADRD - Includes both repurposed drugs (already approved for other conditions) and investigational drugs at various clinical stages - Testing may also involve combinations with non-pharmacologic interventions - Unique/Notable Requirements: - Emphasis on rigorous, translational bioinformatics and experimental approaches - Focus on robust preclinical proof of concept to enable rational drug repurposing and combination therapy - No specific OEMs or commercial products are named, as this is a research grant - Open to a wide range of applicants: educational institutions, nonprofits, government, and businesses - Funding Amount: - $1,000,000 grant - Place of Performance: - National Institutes of Health (NIH)

Description

This Notice of Funding Opportunity invites applications to use mouse models for rigorous preclinical testing of drugs or drug combinations currently used for other conditions, as well as investigational drugs at various stages of clinical development, predicted to be effective in Alzheimer's Disease and related dementias. The initiative supports preclinical testing of repurposable or investigational drug candidates in combination with non-pharmacologic interventions to achieve robust translational outcomes. The goal is to establish proof of concept enabling rational drug repurposing and combination therapy development for treatment and prevention of Alzheimer's Disease and related dementias.

View original listing